Get started
Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LXRX chart


Full chart

LXRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪312.11 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.7454 USD
Net income (FY)
‪−177.12 M‬ USD
Revenue (FY)
‪1.20 M‬ USD
Shares float
‪304.81 M‬
Beta (1Y)
2.27

Employees


Employees (FY)
285
Change (1Y)
+150 +111.11%
Revenue / Employee (1Y)
‪4.22 K‬ USD
Net income / Employee (1Y)
‪−621.47 K‬ USD

About Lexicon Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Michael Exton
Headquarters
The Woodlands
Website
lexpharma.com
Founded
1995
FIGI
BBG000BQ85G2
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

LXRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of LXRX is 0.8634 USD — it has increased by 11.88% in the past 24 hours. Watch Lexicon Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lexicon Pharmaceuticals, Inc. stocks are traded under the ticker LXRX.
LXRX stock has fallen by −20.06% compared to the previous week, the month change is a −55.95% fall, over the last year Lexicon Pharmaceuticals, Inc. has showed a −21.51% decrease.
We've gathered analysts' opinions on Lexicon Pharmaceuticals, Inc. future price: according to them, LXRX price has a max estimate of 10.00 USD and a min estimate of 0.80 USD. Watch LXRX chart and read a more detailed Lexicon Pharmaceuticals, Inc. stock forecast: see what analysts think of Lexicon Pharmaceuticals, Inc. and suggest that you do with its stocks.
LXRX reached its all-time high on Jul 21, 2000 with the price of 344.7500 USD, and its all-time low was 0.7300 USD and was reached on Nov 22, 2024. View more price dynamics on LXRX chart.
See other stocks reaching their highest and lowest prices.
LXRX stock is 21.95% volatile and has beta coefficient of 2.27. Track Lexicon Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lexicon Pharmaceuticals, Inc. there?
Today Lexicon Pharmaceuticals, Inc. has the market capitalization of ‪312.11 M‬, it has decreased by −20.87% over the last week.
Yes, you can track Lexicon Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Lexicon Pharmaceuticals, Inc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
LXRX earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.16 USD resulting in a −10.54% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Lexicon Pharmaceuticals, Inc. earnings.
Lexicon Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪1.75 M‬ USD, despite the estimated figure of ‪2.99 M‬ USD. In the next quarter, revenue is expected to reach ‪7.28 M‬ USD.
LXRX net income for the last quarter is ‪−64.81 M‬ USD, while the quarter before that showed ‪−53.43 M‬ USD of net income which accounts for −21.30% change. Track more Lexicon Pharmaceuticals, Inc. financial stats to get the full picture.
No, LXRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 285.00 employees. See our rating of the largest employees — is Lexicon Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lexicon Pharmaceuticals, Inc. EBITDA is ‪−210.56 M‬ USD, and current EBITDA margin is ‪−14.22 K‬%. See more stats in Lexicon Pharmaceuticals, Inc. financial statements.
Like other stocks, LXRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lexicon Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lexicon Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lexicon Pharmaceuticals, Inc. stock shows the strong sell signal. See more of Lexicon Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.